Abstract
In 1962 Kinsbourne described six infants with a syndrome of myoclonus and “dancing eyes” (opsoclonus-myoclonus syndrome, OMS) [1]. OMS in association with neuroblastoma [2] and other neural-crest-derived tumours has been described in some children (paraneoplastic OMS, OMS-NB+), whilst several other potential causal relationships have also been found (Table 1), but little progress has been made in understanding the etiology and treatment of this syndrome. Recently, however, there has been increasing evidence that OMS may be an autoimmune disease of the central nervous system. This chapter will describe the clinical and immunological features as well as treatment options of OMS.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Kinsbourne M (1962) Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 25:271–276
Soloman GE, Chutorian AB (1968) Opsoclonus and occult neuroblastoma. N Engl J Med 279:475–477
Averbuch-Heller L, Remler B (1996) Opsoclonus. Semin Neurol 16:21–26
Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the pediatric oncology group. Med Ped Oncol 29:284–288
Wilfong AA, Parke JT, McCrary JA (1992) Opsoclonus-myoclonus with Beckwith-Wiedermann syndrome and hepatoblastoma. Pediatr Neurol 8:77–79
Pohl KR, Pritchard J, Wilson J (1996) Neurological sequelae of the dancing eye syndrome. Eur J Pediatr 155:237–244
Altman AJ, Baehner RL (1976) Favorable prognosis for survival in children with coin-cident opso-myoclonus and neuroblastoma. Cancer 37:846–852
Cohn SL, Salwen H, Herst CV et al (1988) Single copies of the n-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus-myoclonus. Cancer 62:723–726
Maddison P, Newsom-Davis J, Mills KR, Souhami RL (1988) Favourable prognosis in Lambert-Eaton myasthenic syndrome and small cell lung carcinoma. Lancet 353:117–118
Tuchman RF, Alvarez LA, Kantrowitz AB et al (1989) Opsoclonus-myoclonus syndrome: correlation of radiographic and pathological observations. Neuroradiology 31:250–252
Ziter FA, Bray PF, Cancilla PA (1979) Neuropathological findings in a patient with neuroblastoma and myoclonic encephalopathy. Arch Neurol 36:51
Ridley A, Kennard C, Scholtz CL et al (1987) Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 110:1699–1709
Kaneko CR (1996) Effect of ibotenic acid lesions of the omnipause neurons on saccadic eye movements in rhesus macaques. J Neurophysiol 75:2229–2242
Pranzatelli MR (1996) The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 19:1–47
Johnson HM, Smith EM, Torres BA, Blalock JE (1982) Regulation of in vitro antibody response by neuroendocrine hormones. Proc Natl Acad Sci USA 79:4171–4174
Munck A, Guyre PM (1991) Glucocorticoids and immune function. In: Ader R, Feiten DL, Cohen N (eds) Psychoneuroimmunology. Academic Press, San Diego, pp 447–472
Sugie H, Sugie Y, Akimoto H et al (1992) High-dose i.v. human immunoglobulin in a case with infantile opsoclonus polymyoclonia syndrome. Acta Paediatr 81:371–372
Nolle MT, Pirofsky B, Gerritz GA, Golding B (1979) Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 36:237–243
Cher LM, Hochberg FH, Teruya J et al (1995) Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer 75:1678–1683
Nitschke M, Hochberg F, Dropcho E (1995) Improvement of paraneoplastic opsoclonus-myoclonus after protein A column therapy. N Engl J Med 332:192
Fisher PG, Wechsler DS, Singer HS (1994) Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr Neurol 10:309–312
Modiano JF, Amran D, Lack G et al (1997) Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopathol 83:77–85
Stangel M, Härtung HP, Marx P, Gold R (1998) Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 153:203–214
Grosse-Wilde H, Blasczyk A, Westhoff U (1992) Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 39:74–77
Blasczyk R, Westhoff U, Grosse-Wilde H (1993) Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341:789–790
Ronda N, Haury M, Nobrega A et al (1994) Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol 70:124–128
Veneselli E, Conte M, Biancheri R et al (1998) Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma. Med Pediatr Oncol 30:15–17
Dyken P, Kolar O (1968) Dancing eyes, dancing feet: infantile polymyoclonus. Brain 91:305–320
Bellur SN (1975) Opsoclonus: clinical value. Neurology 25:502–507
Rivner MH, Jay WM, Green JB, Dyken PR (1982) Opsoclonus in Hemophilus influenzae meningitis. Neurology 32:661–663
Kostulas V, Link H, Lefvert AK (1987) Oligoclonal IgG bands in cerebrospinal fluid, principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol 44:1041–1044
Stephenson JBP, Graham-Pole J, Ogg L, Cochran AJ (1976) Reactivity to neuroblastoma extracts in childhood cerebellar encephalopathy. Lancet 2:975–976
Martin EF, Beckwith JB (1968) Lymphoid infiltrates in neuroblastoma. Their occurrence and prognostic significance. J Pediatr Surg 3:161–164
Ollert MW, David K, Vollmert C et al (1997) Mechanisms of in vivo anti-neuroblastoma activity of human natural IgM. Eur J Cancer 33:1942–1948
David K, Ehrhardt A, Ollert MW et al (1997) Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: correlation to MYCN amplification and effects od retinoic acid. Eur J Cancer 33:1937–1941
Noetzel MJ, Cawley LP, James VL et al (1987) Anti-neurofilament antibodies in opsoclonus-myoclonus. J Neuroimmunol 15:137–145
Connolly AM, Pestronk A, Mehta S et al (1997) Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 130:878–884
Stefansson K, Marton LS, Dieperink ME et al (1985) Circulating autoantibodies to the 200,000-dalton protein of neurofilaments in the serum of healthy individuals. Science 228:1117–1119
Antunes NL, Khakoo Y, Matthay KK et al (2000) Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 22:315–320
Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB (1992) The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 141:881–886
Anderson NE, Rosenblum MK, Graus F (1988) Autoantibodies in paraneoplastic syndromes associated with small cell lung cancer. Neurology 38:1391–1398
Anderson NE, Budde-Steffen C, Rosenblum MK et al (1988) Opsoclonus, myoclonus, ataxia and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine 67:100–109
Jensen KB, Dredge BK, Stefani G et al (2000) Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron 25:359–371
Pranzatelli MR, Huang Y, Tate E et al (1995) Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome. Ann Neurol 37:189–197
Voltz R, Dalmau J, Posner JB, Rosenfeld MR (1998) T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 51:1146–1150
Ichiba N, Miyake Y, Sato K et al (1988) Mumps-induced psoclonus-myoclonus and ataxia. Pediatr Neurol 4:224–227
Sheth RD, Horwitz SJ, Aronoff S et al (1995) Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol 10:297–299
Delreux V, Kevers L, Callewaert A, Sindic C (1989) Opsoclonus secondary to an Epstein-Barr virus infection [letter]. Arch Neurol 46:480–481
Kuban KC, Ephros MA, Freeman RL et al (1983) Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 13(1):69–71
Adams GA, Shochat SJ, Smith EI et al (1993) Thoracic neuroblastoma: a pediatric oncology group study. J Pediatr Surg 28:372–378
Janns A, Wsladky J, Chatten J, Johnson J (1996) Opsoclonus/myoclonus: paraneoplastic syndrome of neuroblastoma. Med Pediatr Oncol 26:272–279
Shapiro B, Shulkin BL, Hutchinson RJ et al (1994) Locating neuroblastoma in the opsoclonus-myoclonus syndrome. J Nucl Biol Med 38:545–555
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Italia
About this chapter
Cite this chapter
Blaes, F., Lang, B. (2002). Opsoclonus-Myoclonus Syndrome in Childhood. In: Vincent, A., Martino, G. (eds) Autoantibodies in Neurological Diseases. Topics in Neuroscience. Springer, Milano. https://doi.org/10.1007/978-88-470-2097-9_12
Download citation
DOI: https://doi.org/10.1007/978-88-470-2097-9_12
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2163-1
Online ISBN: 978-88-470-2097-9
eBook Packages: Springer Book Archive